SPONSOR
Daiichi Sankyo
Total Trials
8
Recruiting
8
Phases
Phase 1, Phase 3, Phase 2, Phase 1, Phase 2
Conditions studied: Non-small Cell Lung CancerAdvanced or Metastatic Adrenocortical CarcinomaMetastatic Castration-resistant Prostate CancerOvarian CancerSolid TumorsMetastatic Solid TumorsAcute Myeloid LeukemiaLeukemiaAdvanced Solid TumorMetastatic Solid Tumor
NCT06809764
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Non-small Cell Lung Cancer
NCT07189403 Phase 1
Recruiting
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
Advanced or Metastatic Adrenocortical Carcinoma
NCT06819007 Phase 3
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Ovarian Cancer
NCT07159126 Phase 1
Recruiting
A Study of DS3610a in Participants With Advanced Solid Tumor
Solid Tumors
NCT06824168 Phase 2
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Acute Myeloid Leukemia
NCT05875168 Phase 1, Phase 2
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Advanced Solid Tumor
NCT06660654 Phase 2
Recruiting
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Advanced Solid Tumor
NCT06362252 Phase 1, Phase 2
Recruiting
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Extensive Stage-small Cell Lung Cancer